242 related articles for article (PubMed ID: 32126974)
1. Bone complications in patients with multiple myeloma in five European countries: a retrospective patient chart review.
Mateos MV; Fink L; Koneswaran N; Intorcia M; Giannopoulou C; Niepel D; Cavo M
BMC Cancer; 2020 Mar; 20(1):170. PubMed ID: 32126974
[TBL] [Abstract][Full Text] [Related]
2. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.
Raje N; Terpos E; Willenbacher W; Shimizu K; García-Sanz R; Durie B; Legieć W; Krejčí M; Laribi K; Zhu L; Cheng P; Warner D; Roodman GD
Lancet Oncol; 2018 Mar; 19(3):370-381. PubMed ID: 29429912
[TBL] [Abstract][Full Text] [Related]
3. [Management of bone disease in myeloma patients: zoledronic acid or denosumab?].
Abe M; Miki H; Nakamura S
Rinsho Ketsueki; 2015 Aug; 56(8):997-1004. PubMed ID: 26345558
[TBL] [Abstract][Full Text] [Related]
4. Denosumab for the treatment of bone disease in solid tumors and multiple myeloma.
Yee AJ; Raje NS
Future Oncol; 2018 Feb; 14(3):195-203. PubMed ID: 29052442
[TBL] [Abstract][Full Text] [Related]
5. Use of Bisphosphonates in Elderly Patients With Newly Diagnosed Multiple Myeloma.
Leng S; Chen Y; Tsai WY; Bhutani D; Hillyer GC; Lim E; Accordino MK; Wright JD; Hershman DL; Lentzsch S; Neugut AI
J Natl Compr Canc Netw; 2019 Jan; 17(1):22-28. PubMed ID: 30659126
[No Abstract] [Full Text] [Related]
6. A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America.
Raje N; Roodman GD; Willenbacher W; Shimizu K; García-Sanz R; Terpos E; Kennedy L; Sabatelli L; Intorcia M; Hechmati G
J Med Econ; 2018 May; 21(5):525-536. PubMed ID: 29480139
[TBL] [Abstract][Full Text] [Related]
7. A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in four European countries: Austria, Belgium, Greece, and Italy.
Terpos E; Jamotte A; Christodoulopoulou A; Campioni M; Bhowmik D; Kennedy L; Willenbacher W
J Med Econ; 2019 Aug; 22(8):766-776. PubMed ID: 30969797
[No Abstract] [Full Text] [Related]
8. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
Henry DH; Costa L; Goldwasser F; Hirsh V; Hungria V; Prausova J; Scagliotti GV; Sleeboom H; Spencer A; Vadhan-Raj S; von Moos R; Willenbacher W; Woll PJ; Wang J; Jiang Q; Jun S; Dansey R; Yeh H
J Clin Oncol; 2011 Mar; 29(9):1125-32. PubMed ID: 21343556
[TBL] [Abstract][Full Text] [Related]
9. Use of bisphosphonates in multiple myeloma patients in Denmark, 2005-2015.
Olesen TB; Andersen IT; Ording AG; Ehrenstein V; Seesaghur A; Helleberg C; Silkjær T; Hernandez RK; Niepel D; Abildgaard N
Support Care Cancer; 2021 Aug; 29(8):4501-4511. PubMed ID: 33458807
[TBL] [Abstract][Full Text] [Related]
10. Treatment for myeloma bone disease.
Yeh HS; Berenson JR
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6279s-6284s. PubMed ID: 17062714
[TBL] [Abstract][Full Text] [Related]
11. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma.
Musto P; Petrucci MT; Bringhen S; Guglielmelli T; Caravita T; Bongarzoni V; Andriani A; D'Arena G; Balleari E; Pietrantuono G; Boccadoro M; Palumbo A;
Cancer; 2008 Oct; 113(7):1588-95. PubMed ID: 18683218
[TBL] [Abstract][Full Text] [Related]
12. Biology and treatment of myeloma related bone disease.
Terpos E; Christoulas D; Gavriatopoulou M
Metabolism; 2018 Mar; 80():80-90. PubMed ID: 29175022
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the clinical benefit of long-term (beyond 2 years) treatment of skeletal-related events in advanced cancers with zoledronic acid.
Henk H; Teitelbaum A; Kaura S
Curr Med Res Opin; 2012 Jul; 28(7):1119-27. PubMed ID: 22536885
[TBL] [Abstract][Full Text] [Related]
14. Real-world treatment patterns and outcomes in non-transplant newly diagnosed multiple Myeloma in France, Germany, Italy, and the United Kingdom.
Mohty M; Knauf W; Romanus D; Corman S; Verleger K; Kwon Y; Cherepanov D; Cambron-Mellott MJ; Vikis HG; Gonzalez F; Gavini F; Ramasamy K
Eur J Haematol; 2020 Sep; 105(3):308-325. PubMed ID: 32418256
[TBL] [Abstract][Full Text] [Related]
15. Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial.
Gimsing P; Carlson K; Turesson I; Fayers P; Waage A; Vangsted A; Mylin A; Gluud C; Juliusson G; Gregersen H; Hjorth-Hansen H; Nesthus I; Dahl IM; Westin J; Nielsen JL; Knudsen LM; Ahlberg L; Hjorth M; Abildgaard N; Andersen NF; Linder O; Wisløff F
Lancet Oncol; 2010 Oct; 11(10):973-82. PubMed ID: 20863761
[TBL] [Abstract][Full Text] [Related]
16. Skeletal-Related Events in Patients With Multiple Myeloma: A Comprehensive Retrospective Cohort Study.
Lee JY; Lee JH; Seo J; Kang M; Jung EH; Kim SA; Suh KJ; Kim JW; Kim SH; Lee JO; Kim JW; Kim YJ; Lee KW; Kim JH; Lee JS; Bang SM
J Korean Med Sci; 2024 Jun; 39(22):e175. PubMed ID: 38859738
[TBL] [Abstract][Full Text] [Related]
17. Bisphosphonates for breast cancer.
Pavlakis N; Schmidt R; Stockler M
Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
[TBL] [Abstract][Full Text] [Related]
18. Bisphosphonates in multiple myeloma: a network meta-analysis.
Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688
[TBL] [Abstract][Full Text] [Related]
19. The role of bisphosphonates in multiple myeloma.
Levy J; Roodman GD
Curr Hematol Malig Rep; 2009 Apr; 4(2):108-12. PubMed ID: 20425422
[TBL] [Abstract][Full Text] [Related]
20. Health resource utilisation associated with skeletal-related events in patients with bone metastases secondary to solid tumours: regional comparisons in an observational study.
Duran I; Fink MG; Bahl A; Hoefeler H; Mahmood A; Lüftner D; Ghazal H; Wei R; Chung KC; Hechmati G; Green J; Atchison C
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 26865392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
